TP53 and neoplasm: The in vitro 3D tumor response to the MDM2 inhibitors was successfully tracked for 2 weeks showing that AMG232 has strong efficacy and selectivity in TP53 wild-type patient-derived glioblastoma stem cells (Fig. 5b and Supplementary Fig. 8).